GlassScriptPhysician profile
Christopher John Connolly
NPI 1881616167
$12,285.00
in general payments reported to CMS, 2019-2025
56 companies · $2,065 in 2025
The $2,065 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $665 · 2021: $1,122 · 2022: $3,698 · 2023: $1,808 · 2024: $1,893 · 2025: $2,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,765.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,811.56 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,324.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $839.62 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $833.67 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $649.74 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $638.89 | 2019-2025 | Airsupra, Breztri, Bevespi Aerosphere |
| Glaxosmithkline, LLC. | $392.75 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Janssen Pharmaceuticals, INC | $360.40 | 2019-2025 | Invega Sustenna, Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $348.51 | 2022-2025 | |
| Corcept Therapeutics | $305.44 | 2024-2025 | Korlym |
| Astellas Pharma US INC | $230.38 | 2019-2025 | Veozah |
| Grifols USA, LLC | $223.66 | 2021-2024 | Prolastin-C Liquid |
| Amarin Pharma, INC. | $188.17 | 2019-2021 | |
| Abbott Laboratories | $158.42 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $154.40 | 2019-2025 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Connolly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.